trial

Study of Immunotherapy in Autoantibody Positive Psychosis

NCTId NCT02449746
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 10 (actual)
Sponsored by University of Cambridge
Primary completion 2017-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
10 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2015-08
Primary completion
2017-08
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Plasma ExchangeIntravenous immunoglobulin

Sponsors

University of CambridgeLead Sponsor
University of OxfordCollaborator
Stanley Medical Research InstituteCollaborator
McPin FoundationCollaborator

Investigators

1
Alasdair Coles, 01223 762016Principal Investigator

Sites

5 total
Birmingham, United KingdomCambridge, United KingdomNottingham, United KingdomOxford, United KingdomSouthampton, United Kingdom

Facts & assertions

4 sourced
Enrollment
10
Phase
NA
Primary Completion Date
2017-08
Status
COMPLETED
relationships
The graph out of here
drug
Plasma Exchange
drug
Intravenous immunoglobulin
drug
lead_sponsor
University of Cambridge
company
collaborator
University of Oxford
company
Stanley Medical Research Institute
company
indication
Autoimmune Diseases
indication
Psychosis
indication
Auto Immune Disorders
indication
investigator
Alasdair Coles, 01223 762016
person